Clinical Trials Logo

Clinical Trial Summary

This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1012. The goal of this clinical trial is to confirm the theraputic effect of segmentectomy for ground glass-dominant invasive lung cancer with size of 2-3cm. The main questions it aims to answer are: - The 5-year disease-free survival of patients having ground glass-dominant invasive lung cancer with size of 2-3cm; - The post-operative lung function tests after receiving segmentectomy. Participants will receive segmentectomy as the surgical procedure.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05717803
Study type Interventional
Source Fudan University
Contact Fangqiu Fu, M.D.
Phone +86-13122677592
Email fufangqiu12@163.com
Status Recruiting
Phase Phase 3
Start date February 15, 2023
Completion date December 31, 2029

See also
  Status Clinical Trial Phase
Recruiting NCT02898857 - Chemoresistance and Involvement of the NOTCH Pathway in Patients With Lung Adenocarcinoma N/A
Completed NCT02127359 - Whole-Exome Sequencing (WES) of Cancer Patients
Recruiting NCT01249066 - Expression of AMP-activated Protein Kinase (AMPK) Protein in Lung Adenocarcinoma N/A
Not yet recruiting NCT04482829 - TCM in the Treatment of Lung Adenocarcinoma N/A
Recruiting NCT04929041 - Testing the Addition of Radiation Therapy to Immunotherapy for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative Phase 2/Phase 3
Terminated NCT04691375 - A Study of PY314 in Subjects With Advanced Solid Tumors Phase 1
Terminated NCT02621333 - Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma Phase 2
Active, not recruiting NCT02282267 - Blood Detection of EGFR Mutation For Iressa Treatment N/A
Not yet recruiting NCT01942629 - Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas N/A
Recruiting NCT01482585 - Study of Early-stage Lung Adenocarcinoma for Early Detection and Effective Treatment Strategy N/A
Recruiting NCT03376737 - Study of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma Phase 2
Recruiting NCT05537922 - I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy
Recruiting NCT04937283 - Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm N/A
Recruiting NCT06255197 - Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers
Completed NCT02093000 - A Study Examining Maintenance Bevacizumab (Avastin®) Monotherapy in Participants With Advanced Lung Adenocarcinoma N/A
Recruiting NCT04119024 - Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors Phase 1
Terminated NCT04682431 - A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors Phase 1
Recruiting NCT05736991 - Deep Learning Signature for Predicting the Novel Grading System of Clinical Stage I Lung Adenocarcinoma
Enrolling by invitation NCT05136014 - Evaluation of the Response to Tyrosine Kinase Inhibitors in Localized Non-small Cell Lung Cancer (NSCLC) Patients With EGFR Mutation in a Patient-derived Organoid Model
Terminated NCT05012397 - Milademetan in Advanced/Metastatic Solid Tumors Phase 2